Skip to main content
Livermore
Livermore
ZHEN

Candel Therapeutics, Inc.

CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001841387

In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Candel Therapeutics, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of CADL: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders841114+31
Shares23.6M2.31M43.4M+22.1M (+103.6%)
Value$133.5M$13.0M$212.9M+$92.4M (+76.7%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (39)

Institutions that held Candel Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to CADL in Q1 2026
InstitutionSharesValue% of portfolio
RTW Investments, LP6,422,018$31.5M0.31%
Saturn V Capital Management LLC2,896,588$14.2M2.57%
Vanguard Capital Management LLC2,462,757$12.1M0.00%
Vestal Point Capital, LP1,125,000$5.51M0.15%
Millennium Management LLC1,060,086$5.19M0.00%
Heights Capital Management, Inc775,000$3.80M1.06%
Vanguard Fiduciary Trust Co280,451$1.37M0.00%
Vanguard Portfolio Management LLC268,249$1.31M0.00%
ExodusPoint Capital Management, LP227,468$1.11M0.01%
Ghisallo Capital Management LLC200,000$980.0K0.03%
Kynam Capital Management, LP200,000$980.0K0.06%
Janus Henderson Group PLC171,978$845.3K0.00%
Woodline Partners LP156,700$767.8K0.00%
Point72 Asset Management, L.P.107,211$525.3K0.00%
Stonepine Capital Management, LLC102,500$502.3K0.44%
Kennedy Capital Management, Inc.92,625$453.9K0.01%
Hudson Bay Capital Management LP59,210$290.1K0.00%
Belpointe Asset Management LLC45,604$223.5K0.01%
Balyasny Asset Management LLC43,208$211.7K0.00%
AlphaCentric Advisors LLC36,313$177.9K0.18%
HRT Financial LP32,015$156.0K0.00%
Creative Planning31,398$153.8K0.00%
Quadrature Capital Ltd21,023$103.0K0.00%
Axq Capital, LP20,864$102.2K0.01%
AQR Capital Management LLC18,028$88.3K0.00%
Simplex Trading, LLC13,216$64.8K0.00%
Renaissance Technologies LLC12,780$62.6K0.00%
Vanguard Global Advisers, LLC12,725$62.4K0.00%
Mirabella Financial Services LLP12,489$61.2K0.01%
Brevan Howard Capital Management LP11,821$57.9K0.00%
MML Investors Services, LLC10,325$50.6K0.00%
Bartlett & Co. Wealth Management LLC3,520$26.5K0.00%
US Bancorp731$3.58K0.00%
Steward Partners Investment Advisory, LLC677$3.32K0.00%
UBS Asset Management Americas Inc138$6760.00%
Allworth Financial LP132$6470.00%
MAI Capital Management39$1920.00%
Essential Partners LLC9$440.00%
Rothschild Investment LLC3$150.00%

Sold out (8)

Institutions that held Candel Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of CADL in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Colony Group, LLC81,816$462.3K
State of Wisconsin Investment Board52,147$294.6K
Virtu Financial LLC26,832$152.0K
Squarepoint Ops LLC19,737$111.5K
Quest Partners LLC11,941$67.5K
Jane Street Group, LLC10,799$61.0K
ProShare Advisors LLC10,433$58.9K
Amalgamated Bank1,377$8.00K

Not filed for Q1 2026 yet (1)

Institutions that held Candel Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CADL in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc2,305,060$13.0M